- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
Pharmacokinetic parameters in children are similar to adults
| Vd | 0,15 l/kg |
| T1/2 | Approx. 28 days |
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Available formulations
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Dosages
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Renal impaiment in children > 3 months
No information available on dose adjustment in renal impairment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects in children
The safety profile in babies, infants, children and adolescents is similar to the adult profile.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions in children
Be careful in children < 1 years of age as the hemostatic system is still immature. The relative concentrations of pro- and anticoagulation proteins and the potential risk of trombosis should be taken into account in this age group.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
| Vitamin K | ||
|---|---|---|
| B02BA01 | ||
| Fibrinogen | ||
|---|---|---|
| B02BB01 | ||
| Local hemostatics | ||
|---|---|---|
| B02BC30 | ||
| Blood coagulation factors | ||
|---|---|---|
| B02BD08 | ||
| B02BD04 | ||
| B02BD02 | ||
| B02BD01 | ||
| Other systemic hemostatics | ||
|---|---|---|
| B02BX05 | ||
| B02BX04 | ||
| Blood coagulation factors | ||
|---|---|---|
| B02BD08 | ||
| B02BD04 | ||
| B02BD02 | ||
| B02BD01 | ||
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Reference
- Roche Registration GmbH, SmPC Hemlibra (EU/1/18/1271/001-004) 05-06-2019, www.ema.europa.eu/en/medicines/human
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Changes
Changes
